Standards, Guidance & Notices
Showing 41–50 of 76
MHLW
Notice
Notice
Admin-Notice-2024-01-31
Q&A on Cybersecurity of Medical Devices (2024 Version)
Expanded Q&A set on application and conformance assessment of Essential Principles Article 12(3). Provides guidance on system architecture diagram formats, post-transition application handling, third-party testing utilization, SBOM documentation scope, and legacy product compliance strategies based on practical implementation experience.
Published: 2024-01-31
JFMDA
Notice
Notice
jfmda_20240129_f5a055dd
English Translation of Cybersecurity and Usability Notification
Notice (29 January 2024) from the JFMDA Legislative Affairs Committee, Review-Related Subcommittee, announcing unofficial English translations, prepared by the PMDA Office of Medical Devices, of three MHLW notifications concerning medical device cybersecurity and usability: (1) Application of Article 12-3 of the Essential Principles for Medical Devices (PSEHB MDED Notification No. 0331-8, 31 March 2023); (2) Confirmation of compliance with Article 12-3 of the Essential Principles for Medical Devices (PSEHB MDED Notification No. 0523-1, 23 May 2023); and (3) Handling of the revised Japanese Industrial Standard (JIS) on usability engineering requirements for medical devices (PSEHB MDED and CND Notification No. 0930-1, 30 September 2022). The page notes that the translations are provided for reference only and that only the original Japanese texts have legal effect.
Published: 2024-01-29
MHLW
Notice
Notice
MHLW-PSEHB-PSD-0115-No.2
Fundamental Approach to Adverse Event Reporting Related to Medical Device Cybersecurity
Notice clarifying handling of cybersecurity events in adverse event/serious adverse event reporting systems. Addresses reporting applicability for patient harm from cyber attacks or vulnerability exploitation, decision-making flowcharts, and manufacturer response procedures. Serves as foundational regulatory documentation for post-market cybersecurity management.
Published: 2024-01-15
MHLW
Notice
Notice
Admin-Notice-2023-12-22-IDATEN-KISAIJIREI
Examples of Application Forms and Supporting Documents for Change Control Plan Confirmation Applications for Software as a Medical Device
Practical worked examples of application forms and supporting documentation for IDATEN change control plan confirmation applications specific to SaMD. Illustrates how to describe proposed changes, set acceptance criteria, and prepare draft revised approval documents. Issued concurrently with the consolidated Q&A revision.
Published: 2023-12-22
MHLW
Notice
Notice
Admin-Notice-2023-12-22-IDATEN-QA
Q&A on Change Control Plan Confirmation Applications for Medical Devices, AI-Enabled Medical Devices, and Software as a Medical Device (Consolidated Revision)
Consolidated revision of Q&A guidance on the IDATEN change control plan confirmation system, integrating three previously separate documents. Adds provisions specific to AI/ML-enabled medical devices and SaMD, requiring submission of procedures for developing and implementing the change control plan and materials for appropriate AI technology management. Reflects startup company needs and accumulated regulatory experience since the system's 2020 launch.
Published: 2023-12-22
EU
MDCG
MDCG
MDCG 2023-4
Medical Device Software (MDSW) – Hardware combinations Guidance on MDSW intended to work in combination with hardware or hardware components
MDCG 2023-4 addresses MDSW that cannot achieve its intended medical purpose without hardware or a hardware component, setting out three regulatory scenarios (desktop PCs and cloud platforms are out of scope): (1) the hardware qualifies as an accessory to the MDSW under MDR Annex VIII classification rules; (2) the hardware is placed on the market as a standalone medical device -- as part of a system (Art. 22), a combination (Art. 2(1)), or an integral component -- in which case the manufacturer may rely on the hardware's MDR conformity for general safety and performance requirements, though clinical evaluation must still cover the combined intended purpose; (3) the hardware is part of a general consumer or wearable product with no medical device/accessory status, in which case the MDSW manufacturer bears sole responsibility for the safety, performance and reproducibility of the combination across all supported configurations, with correspondingly broader post-market surveillance. Illustrative examples include dermal sensor patches and smartwatches (temperature, SpO2, heart rate) paired with a companion app.
Published: 2023-10-01
FDA
CDRH
CDRH
FDA-OTS-Software-2023
Off-The-Shelf (OTS) Software Use in Medical Devices
FDA guidance setting out the recommended documentation in premarket submissions for off-the-shelf (OTS) software incorporated into medical devices, such as operating systems, database management systems, and libraries. A practical basis for managing SOUP (Software of Unknown Provenance). It presents requirements for evaluating and documenting vendor information, known anomalies, and the support life cycle. Referenced in relation to the SOUP management requirements of IEC 62304.
Published: 2023-09-28
MHLW
Notice
Notice
Admin-Notice-2023-07-20
Q&A on Application of Essential Principles Article 12(3) for Medical Devices
Q&A addressing application and conformance assessment of Essential Principles Article 12(3). Covers transition period marketing approval application handling, submission documentation methods, third-party agency utilization for JIS T 81001-5-1 conformance, and reliability document review scope. References related MHLW regulatory notices issued in March and May 2023.
Published: 2023-07-20
FDA
CDRH
CDRH
FDA-Device-Software-Functions-2023
Content of Premarket Submissions for Device Software Functions
FDA final guidance (2023) on the content of software documentation required in premarket submissions (510(k), PMA, De Novo) for SaMD and SiMD. It organizes documentation requirements by documentation level (Basic or Enhanced) and specifies what to include for software design specifications, architecture, verification and validation, and unresolved anomalies. It replaces the 2005 Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices.
Published: 2023-06-14
MHLW
Notice
Notice
Admin-Notice-2023-05-29
Publication of Guidance on Appropriate and Expedited Approval and Development of Software as Medical Devices (SaMD)
Practical guidance on expedited regulatory approval for SaMD including two-stage approval processes. Clarifies early marketing approval application handling across different development stages while maintaining consistent pre- and post-market safety/effectiveness assurance. Developed through public-private-academic collaboration as part of DASH for SaMD strategy, applicable to AI/ML-enabled SaMD.
Published: 2023-05-29
